ADCT
The transcript is the real afterparty
ADC Therapeutics (ADCT) put out its Q2 2026 earnings call transcript, which is basically Wall Street's version of reading the director's commentary after the movie. The earnings release tells you what happened; the call transcript tells you how management plans to spin it, defend it, or maybe quietly slide past the awkward parts.
Why investors care
For a smaller biotech-ish name like ADCT, the vibe of the call can matter almost as much as the numbers. You're usually listening for three things:
- cash burn and runway
- updates on the pipeline and clinical timelines
- any hint that management is getting more bullish — or more defensive — about the business
What to watch next
Because the content here is just the transcript wrapper and not the actual call details, there's no fresh operational bombshell to decode from the page itself. Still, these transcripts can swing sentiment if management talked up execution, narrowed losses, or gave investors a cleaner path to the next catalyst.
Big picture: if the earnings release was the trailer, the transcript is the full behind-the-scenes cut. And sometimes that's where the stock story actually changes.